Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KIO-104

Small molecule · Inhibitor of dihydroorotate dehydrogenase (DHODH) · developed by Kiora Pharmaceuticals

Phase 2 Most advanced trial
KPRX Developer
1 Registered trials

What is KIO-104?

KIO-104 is an ophthalmic formulation for intravitreal injection of KIO-100, a non-steroidal small molecule that inhibits dihydroorotate dehydrogenase (DHODH). It is being studied in macular edema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
dihydroorotate dehydrogenase (DHODH)
Mechanism
Inhibitor of dihydroorotate dehydrogenase (DHODH)
Pathways
pyrimidine biosynthesis
Therapy area
Ophthalmology
Developer
Kiora Pharmaceuticals, Inc. (KPRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06825702 Phase 2 Macular Edema Recruiting KPRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Macular Edema

Other drugs acting on DHODH

More from Kiora Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KPRX page.

Follow KPRX, the company behind KIO-104

See KPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KPRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.